DUBLIN, October 27, 2022 /PRNewswire/ — The report “Myelofibrosis Epidemiology Analysis and Forecast, 2021-2031” has been added to ResearchAndMarkets.com’s offering.
In 8MM, diagnosed incident cases of MF (sum of diagnosed incident cases of PMF and SMF) are projected to increase from 12,276 cases in 2021 to 15,009 cases in 2031, at the Annual Growth Rate (AGR) of 2.23%.
In 2031, China will have the highest number of diagnosed MF incident cases in 8MM, with 9,302 cases, whereas Spain will have the fewest identified MF incident cases with 413 cases.
In 8MM, diagnosed prevalent MF cases (sum of diagnosed prevalent PMF and SMF cases) are projected to increase from 69,236 cases in 2021 to 84,311 cases in 2031, at an AGR of 2.18 %.
The publisher’s epidemiologists attribute the increase in diagnosed incident cases and diagnosed prevalent cases of MF to changes in diagnosed incidence and survival rates, and population dynamics in each market .
Scope
-
This report provides an overview of risk factors, associates, and the global and historical trends for MF in eight major markets (8MM: US, France, Germany, Italy, SpainUK, Japaneseand China).
-
It includes a 10-year epidemiological forecast for diagnosed incident and diagnosed prevalent cases of MF, PMF, PET MF, and PPV MF based on county-specific studies published in peer- peer reviewed journals. Diagnosed PMF incident cases were further broken down by sex, age (40-49 years, 50-59 years, 60-69 years, 70-79 years, and =80 years), the mutation-enhanced international prognostic scoring system (MIPSS70+ ) version 2.0 [very low risk (0 points), low risk (1-2 points), intermediate risk (3-4 points), high risk (5-8 points), and very high risk (=9 points)], mutations (JAK2V617F, CALR, and MPL), and anemia (with or without). Diagnosed prevalent PMF cases were broken down by gender and age (40-49 years, 50-59 years, 60-69 years, 70-79 years, and =80 years). The publisher’s epidemiologists also provide the identified sex-specific incidence and diagnosed prevalent cases of PET MF and PPV MF in 8MM for the forecast period.
-
The myelofibrosis epidemiology report was written and developed by Masters and PhD level epidemiologists.
-
The Epidemiology Report is in-depth, high-quality, transparent and market-driven, providing expert analysis of disease trends in 8MM.
Reasons to Buy
-
Develop business strategies by understanding the trends shaping and driving the global myelofibrosis market.
-
Identify patient populations in the global myelofibrosis market to improve product design, pricing, and launch plans.
-
Organize sales and marketing efforts by identifying age groups that present the best opportunities for myelofibrosis therapeutics in each of the covered markets.
-
Understand the extent of myelofibrosis by MIPSS70+ v2.0 risk categories, mutations, and anemia
Main Topics Covered:
1 Myelofibrosis: Executive Summary
1.1 Catalyst
1.2 Related reports
1.3 Upcoming reports
2 Epidemiology
2.1 Background of the disease
2.2 Risk factors and associates
2.3 Global and historical trends
2.4 8MM method of forecasting
2.4.1 Sources
2.4.2 Estimation of assumptions and methods
2.4.3 Diagnosed incident cases of PMF
2.4.4 Diagnosed incident cases of PET MF and PPV MF
2.4.5 MIPSS70+ V2.0 risk categories in diagnosed PMF incident cases
2.4.6 Mutations in diagnosed PMF incident cases
2.4.7 Patients with/without anemia in identified PMF incident cases
2.4.8 Prevalence cases of PMF have been evaluated
2.4.9 Prevalence cases of PET MF and PPV MF were analyzed
2.5 Epidemiological forecast of myelofibrosis (2021-31)
2.5.1 Diagnosed incident cases of PMF
2.5.2 Identified age-specific incidence cases of PMF
2.5.3 Gender-specifically identified PMF incidence cases
2.5.4 Diagnosed PMF incident cases by MIPSS70+ V2.0 risk category
2.5.5 Diagnosed PMF incident cases by mutation
2.5.6 Patients with or without anemia in diagnosed PMF incident cases
2.5.7 Diagnosed PET MF incident cases
2.5.8 Incidence cases of PET MF identified sex-specifically
2.5.9 Diagnosed incident cases of PPV MF
2.5.10 PPV MF incidence cases identified as sex-specific
2.5.11 Widespread cases of PMF have been evaluated
2.5.12 Age-specific prevalence of PMF cases has been identified
2.5.13 Prevalence of PMF cases diagnosed is gender-specific
2.5.14 Prevalence cases of PET MF were analyzed
2.5.15 Prevalence of PET MF cases was diagnosed which was gender specific
2.5.16 Prevalence cases of PPV MF were analyzed
2.5.17 Prevalence of PPV MF cases was assessed as sex-specific
2.6 Discussion
2.6.1 Epidemiological forecast insight
2.6.2 Impact of COVID-19
2.6.3 Limitation of analysis
2.6.4 Strength of analysis
3 Appendix
For more information about this report visit https://www.researchandmarkets.com/r/86hlb2
Media Contact:
Research and Markets
Laura WoodSenior Manager
[email protected]
For EST Office Hours Call +1-917-300-0470
For US/CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
US Fax: 646-607-1907
Fax (outside US): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
See original content:https://www.prnewswire.com/news-releases/myelofibrosis-epidemiology-analysis-and-forecast-2021-2022–2031-focus-on-united-states-france-germany-italy -spain -uk-japan-and-china-301661129.html
SOURCE Research and Markets